CENTER VALLEY, Pa.,
Nov. 16, 2016 /PRNewswire/
-- Olympus America Inc., a global technology leader in
designing and delivering innovative solutions for medical and
surgical procedures, among other core businesses, has received
510(k) clearance from the U.S. Food and Drug Administration (FDA)
for the company's next-generation laparoscopic PK Morcellator,
paving the way for a complete solution for laparoscopic tissue
containment and extraction.
The Olympus Contained Tissue Extraction System comprises the
PneumoLiner, a first-of-its-kind containment device cleared by the
FDA for gynecologic surgery in April
2016 and the next-generation laparoscopic PK Morcellator to
provide certain patients a laparoscopic surgery option to avoid
open hysterectomy and myomectomy for uterine fibroid removal. The
system was officially introduced November
15 at the American Association of Gynecologic Laparoscopists
(AAGL) Annual Meeting.
The PneumoLiner containment device and PK Morcellator are not
indicated for use in women with tissue that is known or suspected
to contain malignancy; and should not be used for removal of
uterine tissue containing suspected fibroids in patients who are
peri- or post-menopausal, or candidates for en bloc tissue removal
vaginally or via mini-laparotomy.
Gynecologic professional societies—including the American
Congress of Obstetricians and Gynecologists (ACOG), the Society of
Gynecologic Oncology (SGO) and AAGL— have openly voiced concerns
about exposing the majority of women who have benign fibroids
disease to the risk of complications associated with open
procedures.1 The gynecologic professional societies have
indicated that morcellation should not be entirely removed as a
treatment method and that contained tissue extraction may be a
solution.2
"Contained tissue extraction is continually evolving," noted
Arnold P. Advincula, M.D.,
Vice-Chair & Chief of Gynecology at Sloane Women's Hospital,
Columbia University Medical Center/New
York-Presbyterian Hospital. "As surgeons, it is our duty to
evaluate potential solutions to the surgical challenges we face in
clinical practice. We are pleased that Olympus has taken the
initiative to develop a unique and well tested system designed
specifically to facilitate the option for a laparoscopic approach
in women who are at a low risk of having an unexpected malignancy
at the time of surgery."
Contained Tissue Extraction System Explained
The Olympus Contained Tissue Extraction System is the first
complete solution designed for contained tissue extraction to enter
the US market, enabling surgeons to isolate and perform uterine
tissue morcellation and extraction using the PneumoLiner
containment device. The PneumoLiner is currently the first and only
containment device to receive FDA market approval for use with
certain laparoscopic power morcellators to isolate uterine tissue
that is not suspected to contain cancer. Once insufflated, the
PneumoLiner allows space and vision throughout the power
morcellation procedure while maintaining a barrier to the escape of
fluids, cells, and tissue fragments.
When insufflated, the PneumoLiner creates a barrier between the
targeted tissue and non-targeted abdominal contents, to minimize
the risk of inadvertent damage to adjacent structures. When used as
directed, the PneumoLiner significantly reduces the risk of
disseminating cells and tissue into the peritoneal cavity during
power morcellation.
Uterine fibroids are the reason for 30-40 percent of the nearly
600,000 hysterectomies performed in the U.S. each year. The
percentage of these hysterectomies performed using
minimally-invasive surgery (MIS) has increased from approximately
30 percent in 2002 to about 63 percent in 2012, the benefits of
which have been widely documented in retrospective and prospective
studies, and include significant improvements in morbidity and
mortality compared with open surgery.3 Myomectomy, which
is the surgical removal of fibroids while leaving the uterus
intact, has been estimated to be performed laparoscopically
one-third of the time. Prior to its 2014 warning, the FDA estimated
that approximately 60,000 morcellations were performed each
year.4
System Testing and Surgeon Training
Filtration and immersion testing was performed which validated
that the PneumoLiner is impermeable to human cells and that the
containment bag maintains its integrity following morcellation.
Stress testing to evaluate the bag's mechanical strength
demonstrated that the device could withstand forces in excess of
those expected to occur in actual
use.5 PneumoLiner provides adequate
visualization and space to perform morcellation.
Additional testing was performed using the PK Morcellator in
combination with the PneumoLiner to demonstrate compatibility of
the two devices when used together to support the FDA's 510K
clearance of the PK morcellator.
A strict surgeon training protocol is required and has been
validated involving surgeons with varying levels of
experience. Testing conducted with the surgeon training
protocol revealed there was no damage to any of the specimen
containment bags utilized during this process. Consistent
with the FDA's mandate, surgeons who wish to use the containment
system will be required to complete a formal training protocol
before use.
Healthcare Benefits
The Olympus Contained Tissue Extraction System for removal of
uterine tissue in select patients can address key healthcare
objectives:
- Increased Quality Care—The use of a laparoscopic surgical
approach can increase the quality of patient care, as an open
hysterectomy can lead to an increase in major surgical
complications (2.2% to 2.8%) with an increase in hospital
readmission within 30 days (3.4% to 4.2%).6
- Decreased Costs—An increase in quality care leads to a decrease
in overall patient costs, as the median episode cost for
readmission was noted in one study to be $5,847, with a range of $5,478-$10,389.4 A strategy of minimally invasive
laparoscopic hysterectomy is a cost effective surgical method
versus an open hysterectomy, $20,853.15 vs. $30,359.92, respectively.7
- Enhanced Patient Satisfaction—Patients whose surgeons use a
minimally invasive surgical approach may experience fewer
perioperative complications, shorter hospital stays, less pain,
improved quality of life and a faster return to normal activity. A
2016 study by Po et al revealed that 65% of women, after weighing
the risks and benefits, would choose a minimally invasive surgical
approach if the risk of cancer spreading was calculated at 1 in
350, the estimate the FDA evaluated.8
"The Olympus Contained Tissue Extraction System provides
gynecologists and their appropriate, low-risk patients with what
they want again: a choice," said Todd
Usen, President of the Olympus Medical Systems Group at
Olympus Corporation of the Americas. "The Olympus Contained Tissue
Extraction System is the solution that will allow gynecologists to
once again safely and effectively offer minimally invasive
hysterectomies and myomectomies as options to certain low-risk
patients."
The PneumoLiner is manufactured by Advanced Surgical Concepts
(ASC) Ltd. of Bray, Ireland, and
will be exclusively distributed by Olympus America Inc. as part of
the Olympus Contained Tissue Extraction System. The FDA-mandated
training program was developed together by ASC and Olympus. It will
be implemented by Olympus with surgeon validation to ensure that
healthcare professionals use the system safely and effectively.
For more information, to schedule a training session, or to
evaluate the Olympus Contained Tissue Extraction System, please
contact your Olympus representative, or call 800-848-9024 or visit
containedtissueextraction.com.
Press Release Photo
PHOTO CAPTION:
The Olympus Contained Tissue Extraction System, comprised of
the Pneumoliner, a first-of-its-kind containment device cleared by
the FDA in April, and the next generation PK Morcellator, restores
healthcare options for gynecologists and women, and provides
certain patients a laparoscopic surgery option to avoid open
hysterectomy and myomectomy. The system was officially introduced
November 15 at the American
Association of Gynecologic Laparoscopists (AAGL) Annual
Meeting.
About Olympus Medical Systems Group
Olympus Medical Systems Group, a division of global technology
leader Olympus, develops solutions for healthcare professionals to
help improve clinical outcomes, reduce overall costs and enhance
quality of life for patients. By enabling less invasive procedures,
innovative diagnostic and therapeutic endoscopy, and early stage
lung cancer evaluation and treatments, Olympus is transforming the
future of healthcare. For more information, visit Olympus at
medical.olympusamerica.com.
About Advanced Surgical Concepts
Advanced Surgical Concepts (ASC) works closely with surgeons and
specialist clinicians to conceive of new approaches to performing
surgeries. In so doing, ASC designs and develops new medical
devices in order to standardize the methods by which particular
surgeries or diagnostic procedures will be performed. For more
information, visit ASC at http://www.advancedsurgical.ie/.
1
https://www.aagl.org/aaglnews/aagl-statement-to-the-fda-on-power-morcellation/
http://www.acog.org/About-ACOG/News-Room/Statements/2015/ACOG-Statement-on-FDA-Regulation-of-Morcellation
https://www.sgo.org/wp-content/uploads/2014/04/SGO-Testimony-to-FDA-on-Power-Morcellation-FINAL.pdf
2
http://www.acog.org/Resources-And-Publications/Task-Force-and-Work-Group-Reports/Power-Morcellation-and-Occult-Malignancy-in-Gynecologic-Surgery
https://www.aagl.org/wp-content/uploads/2014/05/Tissue_Extraction_TFR.pdf
https://www.sgo.org/newsroom/position-statements-2/morcellation/
3
https://www.aagl.org/aaglnews/aagl-statement-to-the-fda-on-power-morcellation/
4
http://www.fda.gov/downloads/NewsEvents/Newsroom/MediaTranscripts/UCM395327.pdf
5
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm494650.htm
6 Harris JA, Swenson CW, Uppal S, et al. Practice
Patterns 326 and Postoperative Complications Before and After Food
and Drug Administration Safety Communication on Power Morcellation.
Am J Obstet Gynecol. 2015.
7 Cost-Effectiveness Analysis of Morcellation
Hysterectomy for Myomas. Pietro
Bortoletto, BS, Brett D.
Einerson, MD, MPH, Emily S.
Miller, MD, MPH, and Magdy P.
Milad, MD, MS
8 Po L, Lee P, The Unintended Consequences of an
FDA Warning: The Case of Power Morcellation in Fibroid Surgery, The
Journal of Minimally Invasive Gynecology. 2016.
Photo - http://photos.prnewswire.com/prnh/20161115/439553
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/olympus-introduces-first-of-its-kind-contained-tissue-extraction-system-restoring-healthcare-option-for-gynecologists-and-women-300363821.html
SOURCE Olympus Corporation of the Americas